Literature DB >> 6538442

In vivo electrochemical and behavioral evidence for specific neural substrates modulated differentially by enkephalin in rat stimulant stereotypy and locomotion.

P A Broderick, E L Gardner, H M van Praag.   

Abstract

The enkephalinamide, D-Ala2-D-Pro5-enkephalinamide monoacetate (WY 42, 186), when systemically administered to male Sprague-Dawley rats, significantly inhibited sniffing, repetitive head movements, and frequency of rearing, stereotyped behaviors which are often associated with nigrostriatal dopamine activation. On the other hand, the locomotor component of amphetamine-induced stereotyped behavior, which is associated with mesolimbic dopaminergic activation, was not inhibited. In vivo electrochemical analysis showed a significant decrease in striatal dopamine release from striatum after systemic administration of D-Ala2-D-Pro5-enkephalinamide monoacetate in chloral hydrate anesthetized rats, whereas the dopamine signal from the nucleus accumbens, a mesolimbic neuroanatomigic modulation of dopamine both behaviorally and biochemically. Also, the concept of separate neural systems for the stereotypic and locomotor components of amphetamine-induced stereotypy is reinforced.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6538442

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  3 in total

Review 1.  Addiction and brain reward and antireward pathways.

Authors:  Eliot L Gardner
Journal:  Adv Psychosom Med       Date:  2011-04-19

2.  Striatal patch compartment lesions reduce stereotypy following repeated cocaine administration.

Authors:  Ryan C Murray; Mary C Logan; Kristen A Horner
Journal:  Brain Res       Date:  2015-06-19       Impact factor: 3.252

3.  GABRA2 rs279858-linked variants are associated with disrupted structural connectome of reward circuits in heroin abusers.

Authors:  Yan Sun; Yang Zhang; Dai Zhang; Suhua Chang; Rixing Jing; Weihua Yue; Lin Lu; Dong Chen; Yankun Sun; Yong Fan; Jie Shi
Journal:  Transl Psychiatry       Date:  2018-07-30       Impact factor: 6.222

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.